Biomarkers of Aneurysm Wall Strength
Biological and Biochemical Markers of Aneurysm Wall Degradation; Towards Non-Invasive Wall Strength Analysis.
1 other identifier
observational
50
1 country
2
Brief Summary
The purpose of this study is to identify possible in vivo biochemical and biological markers related to aortic wall strength.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P25-P50 for all trials
Started Jun 2007
Typical duration for all trials
2 active sites
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
June 1, 2007
CompletedFirst Submitted
Initial submission to the registry
August 22, 2008
CompletedFirst Posted
Study publicly available on registry
August 25, 2008
CompletedPrimary Completion
Last participant's last visit for primary outcome
January 1, 2010
CompletedStudy Completion
Last participant's last visit for all outcomes
January 1, 2010
CompletedAugust 25, 2008
August 1, 2008
2.6 years
August 22, 2008
August 22, 2008
Conditions
Keywords
Outcome Measures
Primary Outcomes (1)
Aneurysm wall strength
Post-operative
Secondary Outcomes (4)
Extra Cellular Matrix components (Glucoaminoglycans)
post-operative
Biochemical blood analysis
post-operative
MMP content
post-operative
Degree of inflammation
Post-operative
Study Arms (3)
1
Patients scheduled for elective conventional aneurysm repair
2
Patients scheduled for emergent conventional aneurysm repair
3
Patients scheduled for aortic bypass surgery
Eligibility Criteria
Tertiary care clinic. Patients scheduled for transbadominal aortic surgery
You may qualify if:
- Patient scheduled for transabdominal aortic surgery
You may not qualify if:
- Patient characteristics and aneurysm anatomy suitable for endovascular repair
- Previous aortic surgery
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (2)
Alysis Zorggroep, Rijnstate Hospital
Arnhem, Gelderland, 6815AD, Netherlands
Radboud University Nijmegen Medical Center
Nijmegen, Gelderland, 6525GA, Netherlands
Biospecimen
whole blood, serum, white cells, urine, tissue
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Study Officials
- PRINCIPAL INVESTIGATOR
Jan Blankensteijn
Radboud University Medical Center
Central Study Contacts
Study Design
- Study Type
- observational
- Observational Model
- CASE CONTROL
- Time Perspective
- PROSPECTIVE
- Sponsor Type
- OTHER
Study Record Dates
First Submitted
August 22, 2008
First Posted
August 25, 2008
Study Start
June 1, 2007
Primary Completion
January 1, 2010
Study Completion
January 1, 2010
Last Updated
August 25, 2008
Record last verified: 2008-08